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Abstract: Background. Biomarkers such as oxidative stress, folate receptor alpha (FR฀) autoimmunity,
and abnormal brain serotonin turnover are common in autism. Methods. Oxidative stress biomarkers
with pro- and antioxidants were measured in the severe form of infantile autism (n = 38) and controls (n
= 24). Children and parents had repeated testing for serum FR autoantibodies, spinal fluid dopamine
and serotonin metabolites, pterins, and N5-methyltetrahydrofolate (MTHF). Statistical analysis assessed
correlations between variables. Genetic analysis included the SLC6A4 and SLC29A4 genes encoding
synaptic serotonin reuptake proteins. Results. Compared to controls, the autism group showed a signif-
icant increase in oxidative DNA damage in lymphocytes, plasma ceruloplasmin and copper levels with a
high copper/zinc ratio, thiol proteins, and superoxide dismutase (SOD) activity. Vitamin C levels were
significantly diminished. In most autistic patients, the vitamin A (64%) and D (70%) levels were low.
Serum FR autoantibodies fluctuating over 5–7 week periods presented in 68% of all autistic children, 41%
of parents vs. 3.3% of control children and their parents. CSF showed lowered serotonin 5-hydroxyindole
acetic acid (5HIAA) metabolites in 13 (34%), a low 5HIAA to HVA (dopamine metabolite) ratio in 5
(13%), low 5HIAA and MTHF in 2 (5%), and low MTHF in 8 patients (21%). A known SLC6A4 mu-
tation was identified only in 1 autistic child with low CSF 5HIAA and a novel SLC29A4 mutation was
identified in identical twins. Low CSF MTHF levels among only 26% of subjects can be explained by
the fluctuating FR antibody titers. Two or more aberrant pro-oxidant and/or antioxidant factors pre-
disposed to low CSF serotonin metabolites. Three autistic children having low CSF 5HIAA and elevated
oxidative stress received antioxidative supplements followed by CSF 5HIAA normalisation. Conclusion.
In autism, we found diverse combinations for FR autoimmunity and/or oxidative stress, both amenable
to treatment. Parental and postnatal FR autoantibodies tend to block folate passage to the brain affect-
ing folate-dependent pathways restored by folinic acid treatment, while an abnormal redox status tends
to induce reduced serotonin turnover, corrected by antioxidant therapy. Trial Registration. The case-
controlled study was approved in 2008 by the IRB at Liège University (Belgian Number: B70720083916).
Lay Summary. Children with severe infantile autism frequently have serum folate receptor autoantibod-
ies that block the transport of the essential vitamin folate across the blood-brain barrier to the brain.
Parents are often asymptomatic carriers of these serum folate receptor autoantibodies, which in mothers
can block folate passage across the placenta to their unborn child. This folate deficiency during the child’s
intrauterine development may predispose to neural tube defects and autism. Oxidative stress represents
a condition with the presence of elevated toxic oxygen derivatives attributed to an imbalance between the
formation and protection against these toxic reactive oxygen derivatives. Oxidative stress was found to
be present in autistic children where these reactive oxygen derivatives can cause damage to DNA, which
changes DNA function and regulation of gene expression. In addition, excessive amounts of these toxic
oxygen derivatives are likely to damage the enzyme producing the neuromessenger serotonin in the brain,
diminished in about 1/3 of the autistic children. Testing children with autism for oxidative stress and its
origin, as well as testing for serum folate receptor autoantibodies, could open new approaches towards
more effective treatments.
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Background. Biomarkers such as oxidative stress, folate receptor alpha (FRα) autoimmunity, and abnormal brain serotonin
turnover are common in autism. Methods. Oxidative stress biomarkers with pro- and antioxidants were measured in the severe
form of infantile autism (n� 38) and controls (n� 24). Children and parents had repeated testing for serum FR autoantibodies,
spinal fluid dopamine and serotonin metabolites, pterins, and N5-methyltetrahydrofolate (MTHF). Statistical analysis assessed
correlations between variables. Genetic analysis included the SLC6A4 and SLC29A4 genes encoding synaptic serotonin reuptake
proteins. Results. Compared to controls, the autism group showed a significant increase in oxidative DNA damage in lymphocytes,
plasma ceruloplasmin and copper levels with a high copper/zinc ratio, thiol proteins, and superoxide dismutase (SOD) activity.
Vitamin C levels were significantly diminished. In most autistic patients, the vitamin A (64%) and D (70%) levels were low. Serum
FR autoantibodies fluctuating over 5–7 week periods presented in 68% of all autistic children, 41% of parents vs. 3.3% of control
children and their parents. CSF showed lowered serotonin 5-hydroxyindole acetic acid (5HIAA) metabolites in 13 (34%), a low
5HIAA to HVA (dopamine metabolite) ratio in 5 (13%), low 5HIAA and MTHF in 2 (5%), and low MTHF in 8 patients (21%). A
known SLC6A4 mutation was identified only in 1 autistic child with low CSF 5HIAA and a novel SLC29A4 mutation was
identified in identical twins. Low CSF MTHF levels among only 26% of subjects can be explained by the fluctuating FR antibody
titers. Two or more aberrant pro-oxidant and/or antioxidant factors predisposed to low CSF serotonin metabolites. 'ree autistic
children having low CSF 5HIAA and elevated oxidative stress received antioxidative supplements followed by CSF 5HIAA
normalisation. Conclusion. In autism, we found diverse combinations for FR autoimmunity and/or oxidative stress, both
amenable to treatment. Parental and postnatal FR autoantibodies tend to block folate passage to the brain affecting folate-
dependent pathways restored by folinic acid treatment, while an abnormal redox status tends to induce reduced serotonin
turnover, corrected by antioxidant therapy. Trial Registration. 'e case-controlled study was approved in 2008 by the IRB at Liège
University (Belgian Number: B70720083916). Lay Summary. Children with severe infantile autism frequently have serum folate
receptor autoantibodies that block the transport of the essential vitamin folate across the blood-brain barrier to the brain. Parents
are often asymptomatic carriers of these serum folate receptor autoantibodies, which in mothers can block folate passage across
the placenta to their unborn child. 'is folate deficiency during the child’s intrauterine development may predispose to neural
tube defects and autism. Oxidative stress represents a condition with the presence of elevated toxic oxygen derivatives attributed to
an imbalance between the formation and protection against these toxic reactive oxygen derivatives. Oxidative stress was found to
be present in autistic children where these reactive oxygen derivatives can cause damage to DNA, which changes DNA function
and regulation of gene expression. In addition, excessive amounts of these toxic oxygen derivatives are likely to damage the
enzyme producing the neuromessenger serotonin in the brain, diminished in about 1/3 of the autistic children. Testing children
with autism for oxidative stress and its origin, as well as testing for serum folate receptor autoantibodies, could open new
approaches towards more effective treatments.
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1. Introduction
Studies in autistic twins indicate involvement of both genetic
and environmental factors. However, no common final
pathway leading to autism spectrum disorders has been
identified, apart from rare monogenetic, infectious, toxic, or
environmental causes [1, 2]. 'e possible attribution by
epigenetic factors came from postmortem brain tissue
findings supporting a role of microRNA dysregulation in the
pathophysiology of autism [3]. Recent studies have identi-
fied altered levels of salivary microRNA profiles in autism,
differentiating autism spectrum disorders from peers with
typical development and nonautistic developmental delay
[4].
During the prenatal period, sufficient folate delivery to
the developing embryo is necessary to prevent neural tube
defects (NTDs) and autism spectrum disorders (ASDs)
[5–7]. Despite normal maternal folate status during preg-
nancy, maternal serum FRα autoantibodies can impair folate
passage across the placenta and predispose the fetus to NTD
or autism [8, 9]. 'e prevalence of maternal FRα autoan-
tibodies in families with autism varied between 26–59%
while the prevalence of paternal FRα antibodies varied
between 18–69% [9, 10]. Postnatal acquisition of FRα au-
toantibodies can cause infantile-onset cerebral folate defi-
ciency (CFD) syndrome and autism spectrum disorders
[11, 12]. 'e prevalence of FRα autoantibodies for autistic
children varied between 47–76% [9, 10]. 'e prevalence of
FRα antibodies in healthy adult women was estimated at
4–7% in Spain, 9–13% in Ireland, and 10–15% in the US
population. A low titer of this antibody in a fraction of the
adult population appears to be nonpathologic [9].
'e cerebral folate deficiency (CFD) syndrome is defined
as any neuropsychiatric condition with low CSF N5-meth-
yltetrahydrofolate (MTHF), where FRα antibodies were
identified in the majority of cases, while FOLR1 gene mu-
tations or mitochondrial disorders remain rare alternative
causes [12–15].
Based upon findings in mitochondrial encephalopathies,
Kearns–Sayre syndrome, and Alper’s disease, reactive oxy-
gen species (ROS) and low ATP production were suspected
to reduce MTHF stability and impair folate transport to the
brain. In vitro studies showed that in KB cells (ubiquitous
keratin-forming tumor cell line HeLa), expressing the FRα
and the reduced folate carrier (RFC1), MTHF uptake was
impaired following exposure to reactive oxygen species
(ROS). 'is could be prevented by the radical scavenger
ascorbic acid as an antioxidant [16]. In patients with mi-
tochondrial encephalopathies, the imbalance between ROS
formation and antioxidant defenses causes oxidative stress
and damage to reduced folates and to folate transporter
proteins [16], explaining the instability of reduced folates
and disruption of folate transfer across the blood-CSF
barrier. Although evidence is limited in autism, prior studies
have suggested increased vulnerability to oxidative stress
and decreased methylation capacity in its pathogenesis
[17–19]. 'e different effects exerted by ROS and the nitric
oxide (NO) derived peroxynitrite radical (nitrosative stress)
upon one-carbon metabolism and passage of MTHF across
placenta and blood-brain barriers as well on DNA damage
are explained by Figure 1. ROS inhibit the methionine
synthase activity and remethylation cycles. Simultaneously,
ROS stimulate cystathionine beta synthase activity shifting
homocysteine from the methionine cycle into the trans-
sulfuration pathway, thereby increasing glutathione pro-
duction. Increased ROS favour DNA oxidation, while
superoxide radicals promote peroxynitrite formation with
consequent nitrosative stress. 'e consequences of blocked
folate passage to the CNS, the impact by ROS and nitrosative
stress upon one-carbon metabolism, DNA stability, neu-
rotransmitter synthesis, and NO production are depicted in
Figure 1.
Brain PET scan studies using the radioactive serotonin
precursor α[11C]-methyl-L-tryptophan indicated dimin-
ished whole brain or regional serotonin levels in autistic
children compared to controls [21]. However, the com-
promised brain serotonin status remains an enigma. After
transport of the amino acid precursor L-tryptophan (Trp)
across the blood-brain barrier and its uptake by specific
serotonin producing raphe neurons, the first rate-limiting
step of serotonin synthesis is mediated by the neuronal
enzyme tryptophan hydroxylase 2 (TPH2). 5-Hydroxy-
tryptophan (5OH-Trp) will be decarboxylated by the vitamin
B6-dependent enzyme aromatic amino acid decarboxylase
to serotonin (5HT; 5-hydroxytryptamin). Serotonin is then
packaged by the action of vesicular monoamine transporter
isoform 2 (VMAT-2). Vesicular serotonin is released at
axonal terminals into the synapse for subsequent action at
postsynaptic serotonin receptors. Serotonin is cleared from
the synaptic cleft through action of the serotonin reuptake
transporter (SERT) into the presynaptic space and partly
through two other serotonin reuptake transporters located
in neurons and glial cells surrounding the synapse, being the
plasma monoamine transporter (PMAT) and the organic
cation transporter (OCT). After re-entry into the presyn-
aptic space, part of the serotonin pool will be recycled into
vesicles and part will be catalyzed by monoamine oxidase-A
(MAO-A) and aldehyde dehydrogenase to the serotonin
end-metabolite 5-hydroxyindoleacetic acid (5HIAA). 'e
three most important enzymes and transport proteins that
determine serotonin homeostasis and turnover in the CNS
are TPH2, SERT, and MAO-A (Figure 2).
Clinical anecdotal reports and animal and genetic studies
in ASD have addressed the serotonin enigma. In comparison
with healthy age-matched controls, a previous spinal fluid
study among 97 ASD patients confirmed low CSF levels for
the serotonin end-metabolite 5-hydroxyindole acetic acid
(5HIAA) levels among 31% of the patients and low MTHF
levels in 21% of patients, while 48% of all patients had
normal CSF findings [22]. A genetic study on 248 ASD
patients including the 97 patients having the CSF analysis
found a p.Gly56Ala mutation in the SLC6A4 gene with a
gain of function of the SERTprotein at an equal frequency in
the ASD and control populations. In contrast, among the
248 ASD patients, a prevalence (3.2%) was detected for three
novel heterozygous nonsynonymous mutations within the
SLC29A4 plasma monoamine transporter gene (PMAT),
revealing significantly reduced reuptake activity towards a
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variety of substrates including serotonin, dopamine, and 1-
methyl-4-phenylpyridinium (MPP+). However, these ge-
netic studies linking SLC29A4 gene mutations encoding
PMAT to the ASD population did not always coincide with
low CSF 5HIAA metabolites. PMAT dysfunction in ASD
subjects was speculated to raise serotonin prenatally,
exerting a negative feedback inhibition through serotonin
receptors on development of serotonin networks and local
serotonin synthesis.
Despite the known heterozygous p.Gly56Ala mutation in
the SLC6A4 gene, found in the ASD and control populations, a
recent study in a mouse model showed a substantial impact of
the maternal SLC6A4 (SERT) homozygous p.Gly56Ala ge-
notype on early placental serotonin levels, forebrain serotonin
levels, and neurodevelopment [23].
'e link between brain hyposerotonin and autism was
also supported by the neuronal TPH2 gene knockout mouse
model predisposing to lowered brain serotonin production
[24]. However, the contribution of genetic factors affecting
serotonin in ASD remains weak. Other nutritional factors
like vitamin D status have been shown to play a role in
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Figure 1: Pathophysiology of autism based on our findings showing the impact of reactive oxygen species (ROS) at different levels of
intermediary metabolism and the consequences of brain 5-methyltetrahydrofolate (5-methyl THF) deficiency due to FRα auto-
immunity. ROS inhibits B12-methionine synthase (B12-MS) activity and stimulates cystathionine beta synthase (CBS) activity,
shifting the homocysteine accumulation from the methionine cycle into the transsulfuration pathway with increased production of
the natural antioxidant glutathione. Superoxide anions also react with NO at the level of NO-synthase (NOS1) to form peroxynitrite
instead of NO, which predisposes to apoptosis and nitrosylation of tyrosine and cysteine. Nitrosative stress affects activity of
tryptophan (TPH2) and tyrosine hydroxylases (TH), the rate-limiting enzymes for serotonin, and dopamine synthesis. In addition,
ROS catabolize 5-methyl-THF and impair folate uptake and transcellular transport across the choroid plexus and placental barriers
due to interaction with FRα and RFC1 folate transporters. FRα autoantibodies also impair folate transport to the fetus and brain. 'e
resulting brain folate deficiency predisposes to reduce SAM production and SAM-dependent methyl-transfer reactions and reduces
purine and thymidine synthesis with diminished GTP and BH4 production. 'e diminished BH4 availability as the shared cofactor of
the enzymes TH, TPH2, and NOS1 will therefore reduce their enzyme activity. Reduction of the activated methyl group donor SAM
downregulates DNAmethylation and affects posttranslational modifications of histones (methylation and trimethylation of histones),
thereby impeding the homeostatic balance between gene transcription and silencing. In addition, folate deficiency is accompanied by
overexpression of histone deacetylases, which further leads to abnormal gene silencing. 'e shutdown in expression of specific sets of
genes will affect neuronal growth, pruning, and differentiation. Abbreviations: GTPCH: GTP-cyclohydrolase I; Arg: arginine; Cyst:
cysteine; Tyr: tyrosine; Trp: tryptophan; MTHFR: methylenetetrahydrofolate reductase; RFC1: reduced folate carrier-1 (reproduced
with permission from [20]).
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in transcriptional regulation of neuronal TPH2, SERT, and
monoamine oxidase-A (MAO-A) governing serotonin ho-
meostasis [25, 26]. Vitamin D acts through vitamin D re-
sponse elements (VDREs) at these genes through activation
of TPH2 gene transcription and simultaneous inhibition of
SERT and MAO-A gene expression. 'erefore, vitamin D
deficiency predisposes to low serotonin production and
increased reuptake and catabolism of serotonin in the brain.
Data supporting an increased risk for autism in the offspring
due to maternal intake of selective serotonin reuptake in-
hibitors have remained inconclusive [27].
To address these unresolved issues of serotonin meta-
bolism, the objective of this case-controlled study in infantile
autism was to analyze simultaneously CSF neurotransmitter
and folate metabolites and serum FRα antibodies in children
and their parents and to identify the role of oxidative stress
with elevated pro-oxidants or failing antioxidant defenses. In
addition, we analyzed vitamin A and D levels because these
vitamins are putative antioxidants and vitamin D plays a role
in maintaining serotonin homeostasis and folate transport
across the blood-brain barrier [28]. 'e analysis of our data
of this study examined a postulated link between FRα au-
toantibodies and oxidative stress on one hand and on the
other hand deranged folate transfer to the brain, as well as
deranged brain neurotransmitter metabolism, in particular
serotonin turnover (see Figure 2).
2. Patients and Methods
2.1. Participants. 'e participants recruited for this study
were children referred to our center of autism for diagnosis
and treatment. Investigations included the ADI-R and
ADOS tests, Childhood Autism Rating Scale (CARS), de-
velopment and speech assessment, psychological and psy-
chiatric assessment, and observational evaluation at school
or in the domestic situation. 'e CARS assessment at
baseline performed in 38 autistic patients showed a severe
form of infantile autism in the majority of 34 patients (CARS
between 37 and 60; mean± SD: 43.76± 7.11) and mild to
moderate autism in 4 patients (CARS between 30 and 36.5).
Each patient had a complete history, physical and
neurologic examination, brain MRI, and prolonged EEG
recording. Other investigations included metabolic
screening and measuring urinary amino acids and organic
acids, creatine, and guanidinoacetate excretion. Genetic
testing included Angelman syndrome, fragile X-syndrome,
the MECP2 gene mutations, chromosome analysis, and
array CGH to detect microdeletions or microduplications.
In total, we only recruited 38 patients older than 3½ years,
diagnosed with nonsyndromic infantile autism after ex-
clusion of brain abnormalities, intractable epilepsy, and
metabolic and recognizable genetic abnormalities or syn-
dromes. In the autism group, all parents were healthy
without a neurologic or psychiatric history. Other inclusion
criteria for the autistic children comprised the absence of a
special diet, any medication or supplements, and finally no
specific behavioral intervention at the beginning of this
study. 'e control group consisted of 24 age-matched
healthy children and parents.
2.2. Design of Case-Control Study on Oxidative Stress, FR
Autoimmunity, and CSF Metabolites. 'e study was ap-
proved by the University Hospital Liège Ethics Committee and
the IRB at SUNY Downstate Medical Center, New York.
Children with infantile autism (n� 38) and healthy controls
(n� 24) were at least 3½ years old. After parental informed
consent and overnight fasting, each autistic child or healthy
control had blood samples taken for oxidative stress parameters
and serum FRα-autoantibodies while simultaneously a spinal
tap was performed for the autistic children. For both groups,
blood was drawn for measurement of oxidative stress pa-
rameters as well as pro-oxidant and antioxidant factors (see
below). Results obtained in the autism group were compared
with the healthy age-matched control group by statistical
analysis (see below). Serum from patients was analyzed for
FRα-autoantibodies of the blocking and binding type and
compared to healthy controls. Parents of both groups were
asked to participate in the serum FRα antibody testing. On
follow-up, serial samples for detection of FRα antibodies were
drawn at one-week intervals in 6 children with autism, in-
cluding one monozygotic twin pair. Following the spinal tap,
we analyzed cerebrospinal fluid (CSF) biogenic monoamine
metabolites, pterins, andMTHF. For each autistic child, we also
determined fasting plasma amino acids.
2.3. Oxidative Stress and Pro-Oxidant and Antioxidant
Biomarkers. In the present case-control study, oxidative
stress status was investigated bymeasuring oxidative damage
to lipids and DNA and levels of natural pro-oxidants, an-
tioxidants, and free radical scavengers (supplement 1).
Biomarkers for oxidative stress were lipid peroxides, oxi-
dized LDL, and antibodies against oxidized LDL proteins,
while the comet assay measured the percentage of DNA
damage by detecting single/double-strand DNA breaks,
alkali labile sites (apurinic/apyrimidinic sites), DNA cross-
links, base/base-pair damages, and apoptotic nuclei
in lymphocytes [29]. For the antioxidant defenses, we
measured paroxonase, total and oxidized glutathione, thiol
proteins, ceruloplasmin, apolipoprotein-B, vitamins C and
E, ubichinon-Q10, gamma-tocopherol, beta-carotene, the
antioxidant enzyme glutathione peroxidase and its co-factor
selenium, and superoxide dismutase with its different en-
zyme co-factors copper, zinc, and manganese [30–35]. We
also determined serum iron and ferritin as co-factors of the
antioxidant enzyme catalase. As putative antioxidants, we
also included measurement of vitamin A and D levels.
For the pro-oxidant factors, we measured beta-carotene,
iron, copper, zinc, and the copper-zinc ratio as well as
manganese because elevated values of these metals and trace
elements or an increased copper/zinc ratio act to promote
oxidative stress and the Fenton reaction to generate hydroxyl
radicals [36]. In this context, it should be stressed that some
factors like beta-carotene possess a dual function acting as
antioxidant at physiological concentrations but turning into
a pro-oxidant at elevated concentrations [37].
For each child, the following routine measurements have
also been included: complete blood count (CBC), serum and
RBC folate, vitamin B12, renal and liver function, thyroid
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function (TSH, T3, and T4), lactate, CPK, alkaline phos-
phatase, calcium, magnesium, and cholesterol. Serum
samples were used to measure anti-gliadin antibodies.
2.4. Serum FRα Autoantibodies. 'e assays for both the
blocking and binding FRα autoantibodies have been de-
scribed previously. Blocking FRα autoantibodies in serum
were expressed as pmoles of radioactive folic acid blocked
from binding to FRα-antigen per ml of serum and binding
FRα autoantibodies were expressed as pmoles of IgG anti-
body per ml of serum [38].
2.5. CSF Analysis. After overnight fasting, CSF samples were
collected by lumbar puncture, and measurements included
cells, protein and glucose, the intermediary metabolites
(L-dopa, 3-O-methyl-dopa, and 5OH-Trp) and end-metabo-
lites of dopamine and serotonin, i.e., homovanillic acid (HVA)
and 5-hydroxindole- acetic acid (5HIAA), the pterin metab-
olites neopterin and biopterin, and N5-methyltetrahydrofolate
(MTHF). 'e HVA/5HIAA ratio was calculated. Biogenic
monoamine metabolites have been measured by a HPLC
method. Total neopterin and biopterin (representing the sum
of tetra- and dihydro-biopterin and biopterin) were measured
by HPLC after oxidation with manganese dioxide. MTHF was
measured with HPLC using electrochemical detection. Sepa-
ration was achieved on a 5μ Sperisorb ODS-1 (250× 4.6mm)
analytical column (Stagroma AG, Switzerland), using a 50mM
sodium acetate in 22% (v/v) methanol, pH 4.5 as a mobile
phase. 'e flow rate was 1ml/min, and the analytical cell
(Model 5011, ESA, Bedford,MA,USA)was adjusted to +0.20V
(ESA Coulochem Model 5100A, ESA) with a response time of
2 s. [39–41].
CSF data were compared to previously collected samples
from healthy children classified according to different age
groups at the University Children’s Hospital, Zürich
[39–41]. Because the focus in autism is on reduced serotonin
turnover, we performed appropriate testing of SLC6A4 and
SLC29A4 genes encoding the SERT and PMAT proteins, as
described previously [22].
For a selected group of children with oxidative stress and
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Figure 2: On the left side, the normal intestinal absorption, passage across the blood-brain barrier, and neuronal Trp uptake are shown.
Neuronal Trp will be hydroxylated by tryptophan hydroxylase to 5-hydroxytryptophan (5-OH-Trp) and decarboxylated by aromatic amino
acid decarboxylase to serotonin, which is then transported by the vesicular monamine transporter (VMAT-2) into presynaptic vesicles.
After serotonin releases into the synaptic cleft, part of the serotonin pool will be cleared from the synaptic space by SERTinto the presynaptic
compartment where it will be partly recycled into vesicles or catabolized byMAO to 5HIAA. Another part of the synaptic serotonin pool will
be taken up by PMAT-expressing neurons or OCT-expressing glial cells. On the right, the findings of this study suggest diverse causes
contributing to lowered serotonin turnover. Abundant formation of ROS or peroxynitrite probably represents a major factor involving
TPH2 enzyme dysfunction through oxidation of cysteine rich sites at the Trp binding site. In a minority of cases, a low plasma Trp as
substrate for serotonin (5HT) production may be due to low dietary Trp intake or malabsorption. Rare genetic mutations of the gene
encoding the serotonin reuptake transporter (SERT) lead to a gain of function of serotonin reuptake leading to diminished serotonin
availability at postsynaptic receptors. Other rare mutations affect the gene encoding PMAT involving reduced clearance of serotonin from
synaptic spaces, thereby disturbing serotonin turnover during early fetal brain development.
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evolution was followed after antioxidant treatment as outlined
in a previous study and by supplement 2 and after approval by
the ethics committee and informed consent [20].
2.6. Statistical Analysis. 'e measured oxidative stress
biomarkers and pro- and antioxidants were compared be-
tween the group of autism and healthy age-matched controls
using the unpaired t-test.
Within the autism group, statistical analysis evaluated
correlation coefficients between on one hand the CSF
findings and on the other hand the biomarkers for oxidative
stress, each of the pro-and antioxidant parameters, FR au-
toantibody titers, and the routine parameters iron, ferritin,
and vitamins A and D.
In addition, statistical analysis evaluated the cumulative
number of aberrant pro- and antioxidant parameters present
for each autistic individual compared to each of the oxidative
stress biomarkers and also to the distribution of normal and
abnormal CSF findings for MTHF and biogenic monoamine
metabolites HVA and 5HIAA.
Further statistical analysis used the chi-square test to
validate the different hypotheses evoked by our findings.
3. Results
3.1. Oxidative Stress Biomarkers and Pro- and Antioxidant
Factors. 'irty-eight patients with infantile autism partic-
ipated in this study. 'eir age was 7.25± 3.9 years
(mean± SD) with an age range between 3.6–18 years. 'e
male/female sex ratio was 4.4 :1. For the 24 age-matched
controls, there was an equal gender distribution and com-
pared to the 38 autistic patients, there was no significant
difference with respect to their age of 8.7± 3.2 years that
ranged from 4.4–16 years.
Table 1 shows the results of oxidative stress parameters
between the infantile autism group (n� 38) compared to the
healthy control group (n� 24). 'e statistical test was the
unpaired t-test. Compared to controls, the comet assay
in lymphocytes was the only biomarker for oxidative stress
to show significantly increased values for oxidized DNA,
whereas the other oxidative stress parameters, i.e., plasma
lipid peroxides, oxidized low-density lipoprotein (LDLox),
and antibodies against oxidized LDL, did not differ between
the autistic and healthy control groups. Although the zinc
values in the autistic group remained within the normal
range, the copper and ceruloplasmin values for the autistic
group were significantly higher compared to the control
group. As a consequence, the copper/zinc ratio became
significantly elevated for the autistic group. Among all
measured antioxidant parameters, the vitamin C values were
significantly lowered for the group with autism vs. controls.
Although total glutathione and oxidized glutathione levels
were not different, total thiol-protein levels were signifi-
cantly higher for the autism group. In addition, the values for
superoxide dismutase activity in autism were significantly
raised. Although the putative antioxidants vitamins A and D
were not considered among the antioxidants in this study,
the autistic group had a high prevalence of lowered values
for the putative antioxidants vitamin A (64%) and vitamin D
(70%). Other parameters showed no statistical difference
between autism and controls.
Although there was no consistent statistical difference
for each of all the measured parameters (oxidative stress
biomarkers and antioxidant and pro-oxidant factors) be-
tween the whole group of autistic patients vs. healthy
controls, 25 of the 38 autistic children (66%) had one or a
combination of two elevated oxidative stress biomarkers
(oxidized DNA in lymphocytes above the upper boundary of
the reference range for healthy controls among 12 autistic
patients, elevated lipid peroxides in 2 patients, high oxidized
LDL in 7 patients, and high antibodies against oxidized LDL
in 11 patients). In 20 of these 25 autistic patients with one or
two elevated oxidative stress biomarkers, we found the
presence of one to 4 pro- or antioxidant parameters outside
the normal reference range, defined as values above the
upper boundary or below the lower boundary of the range in
healthy controls (n� 24). However, among 5 out of 25
autistic children with elevated oxidative stress biomarkers
(oxidized DNA damage in 2 patients, combined oxidized
DNA and oxidized LDL in 1 patient, combined oxidized
DNA and antibodies against oxidized LDL in 1 patient, and
combined elevated values for oxidized LDL and antibodies
against LDL in 1 patient), all measured pro- and antioxidant
factors were normal (data not shown). In these latter 5
patients, other pro-oxidant factors predisposing to oxidative
stress, like heavy metal poisoning (aluminium, lead, and
mercury), increased manganese, copper/zinc ratios, or beta-
carotene, were excluded.
However, among the 38 autistic patients, there was a
random distribution of abnormal pro-oxidant and/or an-
tioxidant factors without a clear association between any
specific factor and the different oxidative stress biomarkers.
Eight of the 38 autistic patients had normal pro- and/or
antioxidant parameters, whereas there were 9 patients
having only one abnormal pro-oxidant or antioxidant pa-
rameter, 9 patients with a combination of two, 7 patients
with three, and finally 5 patients with four aberrant pro- and/
or antioxidants. Among all 30 autistic patients with ab-
normal pro- and/or antioxidants, the pro-oxidant factors
included elevated selenium (6 patients) and zinc (5 patients),
an increased copper/zinc ratio (4 patients), and elevated
beta-carotene (1 patient). 'e antioxidant factors in de-
creasing frequency were low iron (9 patients), diminished
apolipoprotein-B (7 patients), low total glutathione (6 pa-
tients), low gamma-tocopherol (5 patients), low manganese
(5 patients), lowered enzyme activity for plasma and red
blood cell glutathione peroxidase (5 patients), low selenium
(4 patients), low vitamin C levels (4 patients), lowered
ferritin levels (3 patients), low Q10 (2 patients), low beta-
carotene (2 patients), and lowered vitamin E levels (1
patient).
We compared each oxidative stress biomarker from the
autism group as a function of the total number of abnormal
pro- and/or antioxidants with the oxidative stress biomarker
values obtained for the healthy control group. Compared to
the control group, the comet assay (oxidized DNA) for
autistic children was significantly increased not only for the
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subgroup having normal pro- and antioxidants but also for
each of the subgroups’ autistic children having only 1 ab-
normal pro- or antioxidant parameter or a combination of 2,
3, or 4 simultaneously measured abnormal pro- and/or
antioxidant parameters. Although numbers are too small to
reach statistical significance, comparison between the sub-
group autistic patients with oxidized DNA within the
normal range and the subgroup with elevated oxidized DNA
above the upper boundary of the healthy control range
demonstrated that the subgroup with elevated oxidized
DNA tended to have low values for the antioxidant enzyme
co-factors manganese and selenium, total glutathione,
gamma-tocopherol, and vitamin E.
'e oxidative biomarker lipid peroxides did not show a
significant difference between the whole autistic group vs.
the healthy control group. In the autistic group, there were
only two patients having an elevated lipid peroxide value
above the upper boundary of the healthy control range.
However, the lipid peroxide levels from the subgroup au-
tistic patients having 2 or more abnormal pro- and/or an-
tioxidant values (mean± SD: 774± 349 μM; n� 21) were
significantly higher in comparison with the lipid peroxides
for the subgroup of autistic patients with either normal or
only one abnormal pro- or antioxidant parameter
(mean± SD: 549± 290 μM; n� 17; t� 2.12; p � 0.04).
Compared to controls, lipid peroxide levels for the autism
subgroup having normal or only one abnormal value for
pro- or antioxidant parameters did not show statistical
difference. However, the lipid peroxide levels for the autistic
subgroup (n� 12) having a cumulative sum of 3 or 4 ab-
normal pro- and antioxidants (mean± SD: 888± 335 μM)
were significantly higher compared to healthy controls
(n� 24; mean± SD: 609± 219 μM; t� 3; p � 0.004).
'e other oxidative stress biomarkers oxidized LDL and
antibodies against oxidized LDL did not show statistically
significant differences between the autism and healthy
control groups. Within the autism group, the latter oxidative
stress biomarkers did not change significantly as a function
of the cumulative number of abnormal pro- and antioxidant
parameters.
3.2. FRαAutoantibodies. Compared to FRα antibodies of the
blocking type in only 1/30 controls, these were present in 26/
38 autistic patients (68%) (chi-square test at 30.12 with
p< 0.001). Upon initial testing, two autistic patients tested
negative but had positive FRα autoantibodies upon follow-
up testing. Among 6 patients, whose serum samples were
collected at 1-week intervals, fluctuating FRα antibody titers
varying from nondetectable levels to high titers were found
in two patients, whereas a minor peak of FR antibodies
occurred once during five weeks in four patients, including
one identical twin pair (Figure 3). Among 26 out of 38
autistic children, the detection of positive FRα autoanti-
bodies of the blocking type (mean± SD for all 38 patients:
0.59± 1.17 pmol FRα antigen blocked/ml serum) was ac-
companied by the simultaneous presence of FRα autoan-
tibodies of the binding type among 6 out of 17 tested
individuals (mean± SD: 0.30± 0.51 pmol IgG/ml serum). In
only 1 autistic child, FRα autoantibodies of the binding type
could be detected in the absence of FRα antibodies of the
blocking type. Among 29 out of 38 families, data were
Table 1: Case-control study comparing oxidative stress parameters (mean± SD) between autistic children and age-matched healthy
controls.
Parameter Autism Controls Reference range for controls Statistics (p value)
Number 38 24
Age (years) 7.25± 3.9 8.7± 3.2 4.4–16 p � 0.13
Comet assay (% oxidized DNA) 24± 9 14.9± 3.9 10.2–21.5 p � 0.0002
Lipid peroxides (μM) 673± 339 609± 219 183–1095 p � 0.41
Oxidized LDL (ng/ml) 1465± 1377 1257± 1111 78–3490 p � 0.54
Antibodies against ox-LDL (IU/L) 747± 428 568± 419 82–1200 p � 0.12
Paroxonase (μM/L) 147± 115 137± 75 3–282 p � 0.73
Copper (mg/L) 1.13± 0.26 0.99± 0.25 0.57–1.78 p � 0.04
Manganese (μg/L) 10.1± 2.58 10± 1.86 6.98–15.24 p � 0.87
Selenium (μg/L) 77.4± 21.2 77.21± 11.53 50.5–98.5 p � 0.96
Zinc (mg/L) 0.84± 0.16 0.84± 0.11 0.59–1.02 p � 1
Ratio copper/zinc 1.34± 0.35 1.17± 0.23 0.74–1.79 p � 0.04
Ceruloplasmin (g/L) 0.31± 0.06 0.28± 0.05 0.18–0.39 p � 0.04
Vitamine C (μg/ml) 11.5± 4.82 14± 2.9 5.14–19.49 p � 0.027
Ubichinon Q10 (mg/L) 0.68± 0.25 0.64± 0.17 0.35–1.06 p � 0.50
Vitamine E (mg/L) 10.08± 2.17 10.7± 2.4 6.4–16.38 p � 0.30
Gamma-tocopherol (mg/L) 0.63± 0.41 0.70± 0.26 0.29–1.28 p � 0.46
Beta-carotene (mg/L) 0.3± 0.29 0.39± 0.25 0.05–0.99 p � 0.22
'iol proteins (μM/L) 402± 47 363± 67 203–436 p � 0.02
Total glutathione (μM/L) 851± 204 811± 141 615–1162 p � 0.40
Oxidized glutathione (μM/L) 1.24± 1.87 1.39± 2 0.53–9.37 p � 0.76
Glutathione peroxidase (IU/g Hb) 42.2± 16.5 40.25± 8.4 25–59 p � 0.60
Superoxide dismutase (IU/g Hb) 1646± 319 1432± 168 1057–1772 p � 0.005
'e reference range for controls shows the upper and lower boundary limits for healthy controls. 'e determined p values using the unpaired student t-test
can be found in the last column.
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available for FRα antibodies in the child and both parents
(Table 2). In this group of 29 families, FRα antibodies of the
blocking type (mean± SD: 0.62± 0.63 pmol FRα antigen
blocked/ml serum) were positive in 20 children from 29
families (69%) with simultaneous presence of FRα anti-
bodies of the binding type in 5 out of 15 tested individuals
(mean± SD: 0.73± 0.61 pmol IgG/ml serum), while only 1
child from these 29 families had FRα antibodies of the
binding type, but no blocking FRα antibodies. Testing of
parents of autistic children available from these 29 families
showed that 12 parents out of 29 families (41%) tested
positive, including either the mother (5/29), the father (3/
29), or both parents (4/29). In contrast, among the control
group of 30 healthy nonautistic children, we only detected
FR antibodies in 1 child and his parents (3.3%). Statistical
analysis indicated a high association of parental FRα anti-
bodies in the autism group (chi-square test at 14.26 with
p< 0.001).
3.3. Spinal Fluid Findings. Normal CSF results were found in
10/38 (27%) of the patients, and abnormal CSF results were
found in the other 28 patients (73%), as shown in Table 3. In 13/
38 patients (34%), 5HIAA levels in spinal fluid were lowered.
Although 5 other patients (13%) had 5HIAA values remaining
within the normal range, the levels remained relatively de-
creased compared to the HVA values as illustrated by higher
HVA/5HIAA ratios above 3.5 (normal range of HVA/5HIAA
ratio from1.5–3.5). In 2 patients (5%), both 5HIAAandMTHF
concentrations were lowered, while in eight patients (21%),
only the CSF MTHF level was lowered.
Considering the presence or absence of oxidative
stress and FRα autoantibodies, four different groups of
patients could be distinguished. Eighteen patients had
both elevated oxidative stress and FR autoantibodies,
which resulted in low 5HIAA in 8 patients, low CSF
MTHF in 3 patients, and normal results in 7 patients. In 7
other patients, there was only evidence for oxidative
stress, which was accompanied by either low CSF MTHF
(1 patient), combined low MTHF and 5HIAA (1 patient),
and decreased or relatively low 5HIAA levels in 5 patients.
FRα autoimmunity without oxidative stress in 6 patients
was associated with either low CSF MTHF in 3 patients,
low 5HIAA in 2 patients, or normal findings in 1 patient.
In 7 patients with absent FRα autoantibodies and no el-
evated oxidative stress biomarkers, abnormalities of CSF
metabolites were still encountered, except in 2 patients
with normal CSF findings. Among several patients having
follow-up for oxidative stress biomarkers, fluctuations of
these biomarkers and the pro- and antioxidant parameters
were noticed. Fasting plasma amino acids showed low Trp
values in 2 patients with low CSF 5HIAA levels, while Trp
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Figure 3: Fluctuations of titers for FR antibodies of the blocking type over 5 weeks in five patients with autism, with the upper left side
showing two patients with high fluctuating FR antibodies of the blocking type and the upper right side showing lower FR antibody
fluctuations in the identical twin pair. Both curves at the lower part represent two other patients having a minor FR antibody peak over a
period of 4 to 5 weeks.
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'e absence of an abnormal redox status or an average
number of 1 aberrant value for pro- and/or antioxidants was
associated with either normal CSF profiles (38–40%), low
CSF MTHF (30%), low CSF 5HIAA (20–23%), or combined
lowering of 5HIAA and MTHF (7–10%). An average
number of two or more than two aberrant pro-oxidant and/
or antioxidant parameters tended to be associated with a
higher prevalence of children with low CSF 5HIAA values
(Figure 4). Statistical analysis confirmed a significant higher
proportion of low CSF 5HIAA levels among children with
two or more than two aberrant pro- and/or antioxidant
parameters compared to the group of children with a normal
redox status or only 1 abnormal pro- and/or antioxidant
parameter (chi-square test at 4.55 with p< 0.05).
Further statistical analysis did not find any other cor-
relation between the values of measured CSF metabolites
and oxidative stress biomarkers, pro- and antioxidant values,
serum and RBC folate, iron and ferritin, vitamins A and D,
and serum FR autoantibody titers. In addition, no corre-
lation was found between the measured titers of FRα au-
toantibodies and oxidative stress biomarkers, pro- and
antioxidant parameters, and vitamins A and D.
3.4. Genetic Findings. Genetic testing in identical twins with
severe autism from consanguineous first-line cousins whose
CSF findings were normal showed the presence of a hetero-
zygous SLC29A4 gene mutation (c.412G>Amutation resulting
in a p.Ala138'r change), encoding a functional loss for the
plasma membrane monoamine transporter (PMAT). 'e as-
sociation of PMAT mutations with autism was previously
reported by our group [22]. In one patient with low CSF
5HIAA, a common heterozygous SLC6A4 gene Gly56Ala
mutation encoding the serotonin reuptake transporter protein
(SERT) was detected. 'is led to a gain of function as reported
previously in another patient [42]. 'e heterozygous SERT
mutation is found at equal frequency in autism and healthy
controls. A 2q22.2-q23.3 microduplication was found in an-
other patient with low 5HIAA levels in CSF, and this
microduplication has been described in the literature to be
associated with developmental delay and autism [43]. An
earlier described Xp22.31 microduplication was found in one
patient with an increased HVA/5HIAA ratio and has been
reported by others [44]. In one patient with normal CSF data,
we found a recently reported 15q11.2 microdeletion [45].
3.5. Effect of Antioxidant Supplementation on CSF
Abnormalities. After identification of low CSF 5HIAA and
oxidative stress in 3 patients of whom 2 had FRα antibodies,
supplements with antioxidants were administered during 8
(patients 1 and 2) or 24 months (patient 3), respectively.
Follow-up spinal tap of these 3 patients showed normal-
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Figure 4: 'e relationship between the serotonin metabolite
5HIAA concentration and redox status. 'is plot shows the cu-
mulative number of antioxidant deficiencies or increased pro-
oxidants on the X-axis and the percentage of patients with low CSF
5HIAA metabolites on the Y-axis, representing the end metabolite
of serotonin production.
Table 2: 'e distribution of blocking and binding FRα autoantibodies in 29 children and their parents.
P−M− P+M− P−M+ P+M+ Total number
Child FRab+ 12 3 3 3 21∗ (0.62 ± 0.63)
Child FRab− 5 2 1 8
Total number 17 3 5 4 29
∗Among 29 autistic children, whose parents have also been tested, 20 had blocking FRα antibodies associated with binding FRα antibodies in only 5 children.
Values in parenthesis (mean± SE: 0.62± 0.63) refer to blocking FRα antibody titers in pmoles FRα blocked/ml serum. In 1 child, only FRα antibodies of the
binding type were found.
Table 3: CSF findings in 38 patients assessed for oxidative stress and FRα autoimmunity.
Cerebrospinal fluid values
5HIAA↓ HVA/5HIAA↑ 5HIAA+F↓ F↓ Normal Total N
Ox stress+ and FRab+ 8 3 7 18
Ox stress+ and FRab− 2 3 1 1 7
Ox stress− and FRab+ 2 3 1 6
Ox stress− and FRab− 1 2 1 1 2 7
Number of patients 13 5 2 8 10 38
F stands for methyltetrahydrofolate (MTHF).
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youngest 3½-year-old autistic child was positive for serum
FRα autoantibodies at low titers which were also present in
the mother but absent in the father. Oxidative stress bio-
markers showed increased lipid peroxides at 1283 μM
(control group mean± SD: 609± 219; range: 183–1095 μM)
associated with low serum apolipoprotein-B at 0.38 g/L
(control group range: 0.60–1.40), low vitamin A and vitamin
E, and low glutathione, selenium, and zinc. CSF showed low
5HIAA at 104 nM and normal HVA values with an elevated
HVA/5HIAA ratio of 5.4 (normal 1.5–3.5) and normal
findings for MTHF and pterins. Daily supplements during 8
months of vitamin C, vitamin E, vitamin A, selenium, and
zinc sulfate resulted in normal CSF findings 10 months later.
'e child showed improved nonverbal communicative skills
and social interaction. His CARS score at baseline was
compatible with severe autism (CARS 42), and following
supplements during 8 months, his CARS decreased towards
34, reflecting moderate autism. 'e second child was 4½
years and had no serum FRα antibodies, whereas his mother
tested positive for FRα antibodies. Oxidative stress included
increased lipid peroxides at 1790 μM (control group
mean± SD: 609± 219; range: 183–1095 μM) attributed to low
co-enzyme Q10, elevated copper and an increased copper/
zinc ratio at 2.34 (normal range: 0.70–1.66), low vitamin A,
and low normal selenium with decreased selenium-depen-
dent glutathione peroxidase activity. CSF showed dimin-
ished 5HIAA at 81 nM (normal range: 105–299) and normal
HVA with an increased HVA/5HIAA ratio at 4.2 (normal
range: 1.5–3.5) in the presence of normal MTHF and pterins.
Daily supplements of co-enzyme Q10, selenium, and zinc
sulfate during 8 months resulted in normal lipid peroxides at
945 μMand normal CSF 5HIAA levels. Clinical amelioration
included improved verbal and nonverbal communication,
first indications of social interaction, disappearance of ag-
itation, and better concentration. However, his CARS score
of 45.5 at baseline only diminished slightly towards 43.5.'e
third patient was 17 years old at the time of investigation and
tested positive for FRα antibodies, while both parents tested
negative. Oxidative stress biomarkers showed increased
oxidized DNA at 29% (control group mean± SD: 14.9± 3.9;
range: 10.2–21.5) attributed to low serum manganese, co-
enzyme Q10, and ferritin values. Plasma L-Trp was low at
15 μM (normal range: 27–75). CSF analysis showed lowered
5HIAA and HVA values with normal MTHF. After he re-
ceived supplements with iron, vitamin C, vitamin E, and
Q10 during 2 years, the result of repeated CSF analysis 2½
years later showed an increase and normalisation of CSF
5HIAA and HVA levels. However, there was minimal
clinical amelioration as was reflected by no significant
change of the severity of autism.'e patient’s older age of 17
years represents a possible negative factor explaining the
poor clinical response despite CSF normalisation.
4. Discussion
'is study suggests that oxidative stress and FRα autoim-
munity represent two independent parameters capable of
affecting DNA integrity, brain neurotransmitters, and folate-
dependent one-carbon metabolism, disrupting epigenetic
programming. 'us, not only treatment for FRα autoim-
munity has to be taken into account [13], but also specific
interventions to neutralize abundant reactive oxygen species
(ROS) which can derange folate homeostasis, serotonin
turnover, intermediary brain metabolism, DNA integrity,
and epigenetics at different levels should be considered. 'e
multiple points where oxidative or nitrosative stress perturb
intermediary metabolism, folate transport, and genetic in-
tegrity have been summarised by Figure 1. A recent treat-
ment trial for autism confirmed a positive effect on outcome
by a combined therapeutic approach that aimed to neutralize
oxidative stress and alleviate FRα autoimmunity [45].
In previous in vitro studies, we found that the generation
of superoxide anions in vitro catabolizes MTHF by 75%
within one hour, which can be prevented by the radical
scavenger ascorbic acid [16]. After exposure to superoxide
anions in culture, cellular folate incorporation was reduced
in KB cells expressing FRα and RFC1 proteins. 'us,
transmembrane MTHF passage at the placenta and choroid
plexus is likely to be impaired by ROS, which leads to fetal
and cerebral folate deficiency. ROS will react with NO-
producing neurons and lead to peroxynitrite formation
within these neurons, which can lead to neuronal dys-
function and eventually apoptosis [46, 47].
In addition to in vivo superoxide anion generation
promoting peroxynitrite formation (Figure 1), additional
neuronal folate depletion lowers purine synthesis and thus
the pool of guanosine triphosphate as substrate for GTP-
cyclohydrolase I, the rate-limiting enzyme for tetrahy-
drobiopterin (BH4) production [48]. Since BH4 acts as
common co-factor for tryptophan- and tyrosine-hydroxy-
lase and NO-synthase, folate depletion will limit serotonin,
dopamine, and NO production.Moreover, in the presence of
low BH4, NO-synthase shifts its enzymatic activity and,
instead of NO formation, starts to produce the nitrosyl
radical peroxynitrite [49]. Moreover, peroxynitrite inacti-
vates tryptophan- and tyrosine-hydroxylases via sulfhydryl
oxidation at their enzyme substrate-binding site, containing
cysteine residues [50, 51].
Peroxynitrite also nitrosylates enzymatic protein tyro-
sine residues, but this exerts a minimal effect [49]. In ad-
dition, oxidation induces neuronal TPH2 aggregates
through disulfide cross-linking [50]. 'us, generation of
ROS and peroxynitrite, enhanced by folate depletion, re-
duces production of dopamine, NO, and in particular se-
rotonin, as confirmed by previous findings of low serotonin
production among 1/3 of autistic patients [21, 22]. 'e
findings of the present study confirm that the cumulative
presence of multiple pro-oxidant factors and/or antioxidant
deficiencies present in each individual increases the per-
centage of patients with low CSF serotonin metabolite
5HIAA (Figure 4). Further evidence supporting our findings
showed that antioxidant supplements for 3 autistic children
with oxidative stress restored low CSF 5HIAA to normal
levels. In this study, two genetic defects involving serotonin
reuptake proteins have only been encountered in 1 patient
and identical twins with autism from consanguineous
parents (first-line cousins). Our prior studies on mutations
of SLC6A4, encoding SERT, and the SLC29A4 gene,
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encoding PMAT, in ASD suggested that normal brain se-
rotonin homeostasis depends on adequate expression of
these genes encoding the serotonin reuptake proteins SERT
and PMAT, which clear serotonin from synaptic clefts and
terminate serotonin signalling [22]. One child in our study
carried a common SLC6A4 mutation with gain of function
of the encoded SERTas previously reported [20]. In identical
twins with normal CSF findings, we performed further
genetic analysis because their parents were first-line cousins,
and we found a SLC29A4 mutation with loss of function of
the PMAT membrane transporter. However, the contribu-
tion by SLC6A4 and SLC29A4 mutations in our study
remained minor with respect to the whole population of
autism spectrum disorders. Another factor predisposing to
low synaptic serotonin availability is the presence of low
vitamin D levels, which normally interact with vitamin D
responsive elements in the promotor region of the TPH2
gene and stimulate its transcription, while vitamin D si-
multaneously represses MAO-A and SERT gene transcrip-
tion [25, 26]. 'us, low vitamin D reduces TPH2 expression
and simultaneously favours higher SERT and MAO-A ex-
pression. However, with a high prevalence of vitamin D
deficiency (70%) in our study, we did not confirm a cor-
relation between plasma vitamin D concentrations and CSF
5HIAA levels (R2� 0.0422). In only two patients with low
CSF 5HIAA levels, we found a low plasma Trp level serving
as substrate to the TPH2 enzyme and partly explaining
lowered brain serotonin production. However, in the other
patients, we did not detect low plasma Trp concentrations.
'ere are a few reports on low urinary Trp excretion
among autistic children on a casein- and gluten-free diet as
well as autistic children without a diet compared to healthy
control children [52]. Other reports confirm low plasma
amino acid precursors (phenylalanine, tyrosine, and tryp-
tophan) as substrates for neurotransmitter synthesis [53].
'is low Trp availability demonstrated by these reports may
be explained further by the known high incidence of feeding
disorders with nutritional deficiencies among children with
infantile autism [20]. 'erefore, care should be taken to
avoid severe feeding disorders and dietary restrictions and to
correct nutritional deficiencies.
Exposure to oxidative stress inhibits B12-dependent
methionine synthase activity, which has a negative impact
on themethionine cycle with reduced S-adenosylmethionine
(SAM) production, resulting in failure of >100 methyl-
transfer reactions. Simultaneously, oxidative stress increases
the activity of cystathionine beta synthase (CBS), which
shifts homocysteine away from the methionine cycle to-
wards the transsulfuration pathway to increase cysteine and
glutathione synthesis as adaptive mechanisms to protect
against elevated oxidative stress. In this context, low brain
MTHF availability due to FRα autoimmunity further in-
hibits methionine synthase activity, enhancing the shift from
the methionine towards the transsulfuration cycle resulting
in downregulation of cellular methylation capacity.
ROS also react directly with DNA purine and pyrimidine
components and causes DNA strand breaks, as reflected by
increased oxidized DNA damage in lymphocytes. Moreover,
ROS can induce oxidative DNA damage at the level of
methylated CpG islands near gene promotor sites resulting
in various mutations including C⟶T transitions, G⟶T
transversions, and CG⟶TT tandem mutations. In addi-
tion, ROS can convert guanosine to 8-oxo-guanosine and 5-
methyl-cytosine towards 5-hydroxymethyl-cytosine
[54–56]. 'ese modified methyl-CpG sequences due to
oxidative stress lead to functional loss of methylated CpG
islands acting as recognition sites for the transcription re-
pression machinery mediating gene silencing [56]. 'us,
oxidative stress not only causes gene sequence alterations
but also results in epigenetic changes with failure of
methylated gene inactivation.
Because FRα autoantibodies block MTHF passage to
the fetus and to the brain, the consequent brain MTHF
depletion diminishes production of sufficient SAM as
substrate of DNA methyltransferases which transfer
methyl groups to CpG promotor sites that serve as rec-
ognition sites required for gene silencing. 'us, the
combination of FRα autoimmunity and oxidative stress
act independently or cooperate to derange epigenetic
mechanisms controlling the orchestration of activation
and inactivation of specific genes during neuronal de-
velopment and differentiation [57, 58].
Table 4: CARS and CSF findings at baseline and following antioxidant supplementation during 8 months (patients 1 and 2) and during 2
years (patient 3) among three children with severe infantile autism.
Patient Age (yr) 5HIAA HVA Ratio MTHF Neo Bio Oxidative stress CARS
(1) Baseline 3½ 104↓ 566 5.4↑ 117 8.6 23 Lipid peroxides↑ 42
Treatment 4½ 160 436 2.7 100 18 37 34
(2) Baseline 4½ 81↓ 338 4.2↑ 95 35 19 Lipid peroxides↑ 45.5
Treatment 5.3 136 495 3.6↑ 113 25 61 Lipid peroxides normal 43.5
(3) Baseline 17 25.6↓ 92↓ 3.6↑ 82.7 9.5 10.7 Ox DNA↑, Trp↓ 41
Treatment 19½ 80 258 3.2 49 10 7↓


















Ratio stands for the HVA/5HIAA ratio with a normal range 1.5–3.5. 'e sign ↑ denotes elevated value, and the sign ↓ denotes diminished value.
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'e consequences of folate deficiency affecting brain
development may be more prominent in autistic children
from mothers with folate deficiency or carrying maternal
FRα autoantibodies during pregnancy. 'is study was not a
treatment trial but an observational study explaining the
diverse results we have obtained. Although for each pa-
rameter the results from the healthy control group did not
always show a statistical difference compared to the autism
group, we defined the upper and lowest boundaries for the
healthy controls as the normal range. We only considered
for the autism group oxidative stress biomarkers and pro- or
antioxidants to be abnormal if the measured values fell
outside this normal range. We found that for each individual
autistic patient, pro- and/or antioxidants can have either
normal values or 1, 2, or more abnormal values, where a
cumulative number of these aberrant factors seems to have
an impact on for example serotonin metabolism.
Among the 38 autistic patients, there was a random
distribution of abnormal pro-oxidant and/or antioxidant
factors without a clear association between any specific
factor and the different oxidative stress biomarkers or CSF
markers.
5. Conclusion
In the pathogenesis of low-functioning autism, oxidative
stress and pre- and/or postnatal folate receptor autoanti-
bodies appear to play an important role by affecting DNA
integrity, intermediary metabolism, serotonin turnover, and
one-carbon transfer mechanisms.'ese changes can have an
impact on epigenetic programming of neurodevelopmental
genes. Early detection and appropriate therapeutic inter-
vention could reverse the core deficits and improve
outcome.
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